- There were around 2,300 new cases of testicular cancer in the UK in 2012, that’s around 6 men every day.
- Testicular cancer is the 16th most common cancer in men in the UK (2012).
- Testicular cancer accounts for less than 1% of all new cases in the UK (2012).
- Testicular cancer has an unusual relationship with age: it is more common in younger men than in older men, with more than 8 in 10 cases diagnosed in the under 50s.
- Only 1% of cases of testicular cancer are diagnosed in men aged 75 and over.
- Testicular cancer is rare before puberty but is the most common cancer in men aged 25-49 in the UK.
- Most testicular cancers occur in descended testicles.
- Since the late-1970s, testicular cancer incidence rates in men have increased by around 90% (89%) in Great Britain.
- Over the last decade, testicular cancer incidence rates in men have increased by around a tenth (9%) in the UK.
- In Europe, around 21,500 new cases of testicular cancer were estimated to have been diagnosed in 2012. The UK incidence rate is 19th highest in Europe.
- Worldwide, around 55,300 new cases of testicular cancer were estimated to have been diagnosed in 2012, with incidence rates varying across the world.
- 1 in 195 men will be diagnosed with testicular cancer during their lifetime.
Testicular cancer statistics
New cases of testicular cancer, 2012, UK
Deaths from testicular cancer, 2012, UK
Survive testicular cancer for 10 or more years, 2010-11, England and Wales
Preventable cases of testicular cancer are not known as it is not clearly linked to any preventable risk factors
- In the UK in 2012 around 60 men died from testicular cancer.
- Testicular cancer death rates have fallen by around 80% since the early 1970s.
- Unlike most cancers, more younger men die from testicular cancer compared to older men.
- Worldwide, around 10,400 men were estimated to have died from testicular cancer in 2012, with mortality rates varying across the world.
- In Europe, around 1,600 men were estimated to have died from testicular cancer in 2012. The UK mortality rate is eighth lowest in Europe.
- Almost all (98%) men diagnosed with testicular cancer in England and Wales survive their disease for ten years or more (2010-11).
- Almost all (98%) men diagnosed with testicular cancer in England and Wales survive their disease for five years or more (2010-11).
- Around all (99%) men diagnosed with testicular cancer in England and Wales survive their disease for one year or more (2010-11).
- Testicular cancer survival is highest for men diagnosed aged under 50 years old.
- Almost all men diagnosed aged 15-49 survive their disease for five years or more, compared with half of men diagnosed aged 80 and over.
- Testicular cancer survival is improving and has increased in the last 40 years in the UK, probably because of combination chemotherapy.
- In the 1970s, around 7 in 10 men diagnosed with testicular cancer survived their disease beyond ten years, now it's around all men.
- When diagnosed at its earliest stage, all men with testicular cancer will survive their disease for five years or more, compared with around 8 in 10 men when diagnosed at the latest stage.
- Testicular cancer is not clearly linked to any preventable risk factors.
- A man’s risk of developing testicular cancer depends on many factors, including age,genetics, and exposure to risk factors.
- No modifiable factors have been conclusively linked with testicular cancer risk, though many factors have been studied. The most well-established risk factor for testicular cancer is cryptorchidism.
- Certain medical conditions and diethylstilbestrol exposure in utero may relate to higher testicular cancer risk, but evidence is unclear.
- ‘Two-week wait’ referral is the most common route to diagnosis of testicular cancer.
- ‘Two-week wait’ standards are met by all countries, ‘31-day wait’ and ‘62-day wait’ are not met by any country for urological cancers.
- Almost 9 in 10 patients had a ‘very good’ or ‘excellent’ patient experience.
- More than 8 in 10 of patients are given the name of their Clinical Nurse Specialist.
The latest statistics available for testicular cancer in the UK are; incidence 2012, mortality 2012 and survival 2010-2011.
European Age-Standardised Rates were calculated using the 1976 European Standard Population (ESP) unless otherwise stated as calculated with ESP2013. ASRs calculated with ESP2013 are not comparable with ASRs calculated with ESP1976.
Lifetime risk estimates were calculated using incidence, mortality, population and all-cause mortality data for 2012.
Survival statistics give an overall picture of survival and (unless otherwise stated) include all adults (15-99) diagnosed, at all ages,
Survival by stage is not yet routinely available for the UK due to inconsistencies in the collecting and recording of staging data in the past. Survival by stage is available for the former Anglia Cancer Network in the east of England, however. The former Anglia Cancer Network covers around 5% of the population of England and may not be representative of the country as a whole due to differences in underlying demographic factors (such as age, deprivation or ethnicity), as well as variation in local healthcare provision standards and policies.
Routes to diagnosis statistics were calculated from cases of cancer registered in England which were diagnosed in 2006-2010.
Cancer waiting times statistics are for patients who entered the health care system within financial year 2014-15. Testicular cancer is part of the group 'Urological cancer' for cancer waiting times data. Codes vary per country but broadly include: penis, prostate, testis, other and unspecified male genital organs, kidney, renal pelvis, ureter, bladder, other and unspecified urinary organs, secondary cancers of kidney, renal pelvis, bladder and other unspecified urinary organs.
Patient Experience data is for adult patients in England with a primary diagnosis of cancer, who were in active treatment between September and November 2013 and who completed a survey in 2014.
You are welcome to reuse this Cancer Research UK statistics content for your own work.
Credit us as authors by referencing Cancer Research UK as the primary source. Suggested styles are:
Web content: Cancer Research UK, full URL of the page, Accessed [month] [year].
Publications: Cancer Research UK ([year of publication]), Name of publication, Cancer Research UK.